These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 32046605)

  • 1. Successful treatment of cholesterol crystal embolism with anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) antibody: a case report.
    Morino J; Hirai K; Kaneko S; Minato S; Yanai K; Mutsuyoshi Y; Ishii H; Matsuyama M; Kitano T; Shindo M; Aomatsu A; Miyazawa H; Ito K; Ueda Y; Ookawara S; Morishita Y
    Ren Fail; 2020 Nov; 42(1):173-178. PubMed ID: 32046605
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of Proprotein Converse Subtilisin/Kexin Type 9 Inhibitor to Treat Cholesterol Crystal Embolisms after Catheterization: A Report of Three Cases.
    Tomoi Y; Soga Y; Imada K; Kodama K; Katsuki T; Hiramori S; Ando K
    Intern Med; 2022 Mar; 61(6):857-860. PubMed ID: 34471031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.
    Zenti MG; Altomari A; Lupo MG; Botta M; Bonora E; Corsini A; Ruscica M; Ferri N
    Eur J Prev Cardiol; 2018 Nov; 25(17):1843-1851. PubMed ID: 30058841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9).
    Gibbs JP; Doshi S; Kuchimanchi M; Grover A; Emery MG; Dodds MG; Gibbs MA; Somaratne R; Wasserman SM; Blom D
    J Clin Pharmacol; 2017 May; 57(5):616-626. PubMed ID: 27861991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab.
    Desai NR; Giugliano RP; Wasserman SM; Gibbs JP; Liu T; Scott R; Sabatine MS
    JAMA Cardiol; 2017 May; 2(5):556-560. PubMed ID: 28122070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Preoperative Administration of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor on Carotid Artery Stenting.
    Shingai Y; Kimura N; Doijiri R; Takahashi K; Yokosawa M; Kanoke A; Kikuchi T; Sugawara T; Tominaga T
    World Neurosurg; 2020 Mar; 135():e36-e42. PubMed ID: 31655235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin.
    Fazio S; Robertson DG; Joh T; Wan H; Riel T; Forgues P; Baum CM; Garzone PD; Gumbiner B
    Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29057618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atopic Dermatitis-Like Rash During Evolocumab Treatment of Familial Hypercholesterolemia.
    Kanda N; Okajima F
    J Nippon Med Sch; 2019; 86(3):187-190. PubMed ID: 31292332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies.
    Gumbiner B; Joh T; Liang H; Wan H; Levisetti M; Vana AM; Shelton DL; Forgues P; Billotte S; Pons J; Baum CM; Garzone PD
    Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29078037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterozygous Ldlr-Deficient Hamster as a Model to Evaluate the Efficacy of PCSK9 Antibody in Hyperlipidemia and Atherosclerosis.
    Wu Y; Xu MJ; Cao Z; Yang C; Wang J; Wang B; Liu J; Wang Y; Xian X; Zhang F; Liu G; Chen X
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31779098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects.
    Wan H; Gumbiner B; Joh T; Riel T; Udata C; Forgues P; Garzone PD
    Clin Ther; 2017 Nov; 39(11):2243-2259.e5. PubMed ID: 29037448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety.
    Lee E; Gibbs JP; Emery MG; Block G; Wasserman SM; Hamilton L; Kasichayanula S; Hanafin P; Somaratne R; Egbuna O
    Clin Pharmacol Drug Dev; 2019 Apr; 8(3):281-289. PubMed ID: 30676701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proprotein Convertase Subtilisin Kexin 9 Inhibitors.
    Pirillo A; Catapano AL
    Cardiol Clin; 2018 May; 36(2):241-256. PubMed ID: 29609754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Sterol Absorption Markers in a Cohort of Real-World Patients.
    Brandt EJ; Benes LB; Lee L; Dayspring TD; Sorrentino M; Davidson M
    J Cardiovasc Pharmacol Ther; 2019 Jan; 24(1):54-61. PubMed ID: 29940784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stabilization of vulnerable carotid plaques with proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab.
    Ogata A; Oho K; Matsumoto N; Masuoka J; Inoue K; Koguchi M; Yoshioka F; Abe T
    Acta Neurochir (Wien); 2019 Mar; 161(3):597-600. PubMed ID: 30729307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9): Impact of PCSK9 on Major Adverse Cardiac and Cerebrovascular Events.
    Akin M; Skripuletz T; Napp LC; Berliner D; Akin I; Haghikia A; Akin E; Bauersachs J
    Cardiovasc Hematol Agents Med Chem; 2017; 14(2):94-100. PubMed ID: 27470008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of proprotein convertase subtilisin/kexin 9 inhibitors in people with diabetes and dyslipidaemia.
    Dijk W; Cariou B
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 1():39-51. PubMed ID: 31002456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of a patient with refractory nephrotic syndrome with PCSK9 inhibitors: a case report.
    Awanami Y; Fukuda M; Nonaka Y; Takashima T; Matsumoto K; Yamasaki M; Miyazono M; Ikeda Y
    BMC Nephrol; 2017 Jul; 18(1):221. PubMed ID: 28683788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors.
    Julius U; Tselmin S; Schatz U; Fischer S; Bornstein SR
    Clin Res Cardiol Suppl; 2019 Apr; 14(Suppl 1):45-50. PubMed ID: 30838555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.